Lampalizumab治疗年龄相关性黄斑变性地图样萎缩的3期试验
Chroma和Spectri两项设计相同的3期双盲随机假手术对照试验共入组1881例双侧地图样萎缩患者,评估玻璃体腔注射lampalizumab(补体因子D抑制剂)48周对萎缩面积扩大的疗效与安全性。结果显示各给药方案与假手术相比均未减少地图样萎缩扩大,未观察到获益,地图样萎缩仍以年均约2 mm²持续扩大。
要点
- Chroma和Spectri试验中lampalizumab各给药方案与假手术相比均未减少地图样萎缩面积扩大。
- 预先设定的亚组(包括补体因子I-profile生物标志物)均未观察到lampalizumab获益。
- 地图样萎缩仍以年均约2 mm²的速度持续扩大。
核心结论
- 在Chroma和Spectri这两项迄今最大规模的地图样萎缩研究中,lampalizumab在48周治疗期间与假手术相比未减少地图样萎缩扩大。
- 结果突显地图样萎缩的显著且持续的扩大,年均约2 mm²。
研究设计与样本
- 两项设计相同的3期双盲、随机、假手术对照临床试验Chroma和Spectri,2014年8月28日至2016年10月6日在23个国家275个中心入组 participant。
- 入组标准为年龄50岁及以上、双侧地图样萎缩、任一眼无既往或活动性脉络膜新生血管,研究眼地图样萎缩病灶面积2.54至17.78 mm²且眼底自发荧光呈弥漫型或带状型。
- 参与者按2:1:2:1随机接受每4周玻璃体腔注射10 mg lampalizumab、每4周假手术、每6周注射10 mg lampalizumab或每6周假手术,持续至96周。
- Chroma入组906例(女553例、男353例,平均[SD]年龄78.1[8.1]岁),Spectri入组975例(女578例、男397例,平均[SD]年龄77.9[8.1]岁),1881例中1733例(92.1%)完成48周研究。
主要发现
- 48周时地图样萎缩病灶面积较基线的校正平均增加量在两项研究所有组中为1.93至2.09 mm²。
- Chroma中每4周lampalizumab组较假手术组的校正平均变化差值为-0.02 mm²(95%CI,-0.21至0.16 mm²;P=.80)。
- Spectri中每4周lampalizumab组较假手术组的校正平均变化差值为0.16 mm²(95%CI,0.00至0.31 mm²;P=.048)。
- Chroma中每6周lampalizumab组较假手术组的校正平均变化差值为0.05 mm²(95%CI,-0.13至0.24 mm²;P=.59),Spectri中为0.09 mm²(95%CI,-0.07至0.24 mm²;P=.27)。
- 截至48周,12447次注射中5次(0.04%)发生眼内炎,1252例接受治疗参与者中5例(0.4%)发生眼内炎。
关键数值与推荐
- 主要疗效指标为48周时地图样萎缩病灶面积较基线的平均变化,基于中央阅片眼底自发荧光图像,在意向治疗人群中比较lampalizumab组与合并假手术组,并按补体因子I-profile遗传生物标志物分析。
- 预先设定的亚组(包括补体因子I-profile生物标志物)均未观察到lampalizumab获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials. OBJECTIVE: To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA. DESIGN, SETTING, AND PARTICIPANTS: Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in the study eye measuring 2.54 to 17.78 mm2 with diffuse or banded fundus autofluorescence patterns. INTERVENTIONS: Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every 6 weeks, or sham procedure every 6 weeks, through 96 weeks. MAIN OUTCOMES AND MEASURES: Safety and efficacy assessed as mean change from baseline in GA lesion area at week 48 from centrally read fundus autofluorescence images of the lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by complement factor I-profile genetic biomarker. RESULTS: A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1] years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD] age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at week 48 were 1.93 to 2.09 mm2 across all groups in both studies. Differences in adjusted mean change in GA lesion area (lampalizumab minus sham) were -0.02 mm2 (95% CI, -0.21 to 0.16 mm2; P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm2 (95% CI, 0.00-0.31 mm2; P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm2 (95% CI, -0.13 to 0.24 mm2; P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm2 (95% CI, -0.07 to 0.24 mm2; P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of lampalizumab was observed across prespecified subgroups, including by complement factor I-profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of 1252 treated participants (0.4%) through week 48. CONCLUSIONS AND RELEVANCE: In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment. Results highlight the substantial and consistent enlargement of GA, at a mean of approximately 2 mm2 per year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02247479 and NCT02247531.
引用
- Holz FG, Sadda SR, Busbee B, et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018. PMID: 29801123. doi:10.1001/jamaophthalmol.2018.1544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。